analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
Published 8 months ago • 685 plays • Length 2:51Download video MP4
Download video MP3
Similar videos
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
4:28
gern stock gern geron coporation top stocks to buy in september
-
4:12
novel therapies in low-risk mds
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
7:05
state-of-the-art treatment regimens for lr-mds
-
1:17
phase ii study of tosedostat in mds
-
0:55
a pooled analysis to determine the optimal ki-67 index cut-off point for predicting outcomes in mcl
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:16
state of the art: mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:19
imetelstat for transfusion-dependent r/r mds
-
2:04
state-of-the-art treatment for hr-mds
-
1:41
an overview of the mds diagnosis pathway